The company’s CLEWICU artificial intelligence software ingests a large range of patient data by linking to electronic medical records, connected medical devices and vital sign monitors, with no need for additional data entry by ICU staff.
In addition to alerting providers to a patient’s potentially deteriorating condition as a diagnostic aid, the system’s real-time risk classification model also predicts which patients may not require any interventions within an eight-hour period.
The FDA also said the standalone CLEWICU software, based within the hospital or in the cloud, could help reduce contact between healthcare workers and COVID-19 patients through remote monitoring.